Semaglutide led to larger reductions in heart failure symptoms and physical limitations compared to placebo, along with reductions in CRP, NT-proBNP, and improvements in 6-minute walking distance and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS). Greater weight loss was also observed compared to placebo. The gene discussed is CRP; the disease is heart failure.